Interpace Biosciences GAAP EPS of -$0.26, revenue of $10.4M

Interpace Biosciences reported Q3 GAAP EPS of -$0.26 and revenue of $10.4M, an 18.7% year-over-year increase, according to the company's press release.

Original reporting
Published Nov 16, 2026, 10:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IDXG
Neutral
high confidence
Mentioned
$IDXG
Relevance
4/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$IDXGNeutralLow
01

Why it matters

The current piece adds no new data, serving only as a recap.

02

Market read

Low relevance; the article repeats already‑public earnings figures without new insight.

03

What to watch

No hidden developments; the article is purely a restatement of prior earnings.

Relevance 4/10Novelty 2/10Timing: none

Background

Interpace Biosciences previously released its Q3 results on 2026-10-15, showing a GAAP loss per share and modest revenue growth.

Company-level read

Ticker impact

$IDXGNeutralHigh confidence
Context

The article reports Interpace Biosciences' Q3 GAAP EPS of -$0.26 and revenue of $10.4M, figures already disclosed 32 days earlier.

Expected impact

little to no impact as the numbers are already known

Evidence & confidence

The data are a repeat of the prior quarter's release, offering no fresh catalyst.

Market effects

None; the biotech sector sees no new driver from this recap.

None; the report is US‑focused but adds no new data.

Minimal

Counterpoint

Investors might view the repeat numbers as a sign of transparency but no actionable edge.

Key entities

  • Interpace Biosciences, Inc.

    Biotech firm reporting Q3 earnings.

Related articles

$IDXGMed

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue ● Preliminary Q3 2026 revenue expected to range from $10.1 million to $10.4 million ● Expected quarter-over-quarter growth of approximately 11% to 14% compared with Q2 2026 ● Expected ye

$IDXGMed

Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results

INTERPACE BIOSCIENCES, INC. (IDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results ● Q2 Revenue of $9.1 million ● Q2 Income from Continuing Operations of $0.3 million ● Q2 Thyroid volume year-over-year increase of 6% ● Q2 Thyroid revenue year-over-year increase of 9%

$ZTEKFMed

Zentek Ltd. (ZTEKF): Financial results for FY2027

Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.